Health Analytics Logo

Publications And Presentations

Health Analytics’ scientific team regularly contributes articles to trade and peer-reviewed publications. Our publications and presentations are just some examples of the many  pertinent resources our company provides for clients, peers, and the healthcare community.


Forma F, Clerie J, Davis T, Clovie K, & Ruetsch C. The Association between Patient Activation and Outcomes among Severely Mentally Ill Patients. J Behav Health Serv Res. (2021); 48(3): 382–399. 

Ruetsch C, Velligan D, Robinson D, Jaeger C, Carpenter W, Davis T, Liberman JN, Clerie J, Waters H, Forma F. Psychiatric Prescriber Attitudes, Experiences, and Proclivities Toward Digital Medicine and How They Influence Adoption of Digital Medicine Platforms. CNS Spectr. (2021) April; 26(2): 144-145. 

Liberman JN, Davis T, Pesa J, Chow W, Verbanac J, Heverly-Fitt S, Ruetsch C. Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care. J Manag Care Spec Pharm. (2020) Aug; 26(8): 987-995. 

Waters HC, Ruetsch C, Tkacz J. A Claims-based Algorithm to Reduce Relapse and Cost in Schizophrenia. Am J Manag Care. (2019) Dec 1; 25(12): e373-e378. PubMed PMID: 31860231.

Ruetsch, C., Un, H., Waters, H.C. (2018). Claims-based proxies of patient instability among commercially insured adults with schizophrenia. Clinicoeconomics Outcomes Research. 7 (10), 259-267.

Velligan, D., Carpenter, W., Waters, H.C., Gerlanc, N.M., Legacy, S.N., Ruetsch, C. (2018). Relapse risk assessment for schizophrenia patients (RASP): A new self-report screening tool. Clinical Schizophrenia and Related Psychoses, 11 (4), 224-235.

Bray, V.J., Broadwell A., Baraf H.S.B., Black S., Brady B.L., Tkacz J., Yarngo L., DeHoratius R.J., (2018) The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients. Drugs in R&D. 2018 Jul 28. doi: 10.1007/s40268-018-0240-1

Ruetsch, C., Tkacz, J., Nadipelli, V.R., Brady, B.L., Ronquest, N., Un, H., Volpicelli, J. (2017) Heterogeneity of nonadherent buprenorphine patients: Subgroup characteristics and outcomes. American Journal of Managed Care, 1 (23), 172-179.

Shafrin, J., May, S.G., Shrestha, A., Ruetsch, C., Gerlanc, N., Forma, F., Hatch, A., Lakdawalla, D.N., & Lindenmayer, J.P. (2017). Access to credible information on schizophrenia patients’ medication adherence by prescribers can change their treatment strategies: Evidence from an online survey of providers. Patient Preference and Adherence, 27 (11), 1071-1081.

Gerlanc, N.M., Cai, J., Tkacz, J.P., Bolge, S.C. Brady, B.L. (2017). The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin. Diabetes, Metabolic Syndrome, and Obesity: Targets and Therapy, 10, 89-99.

Brady, B., Tkacz, J.P., Meyer, R., Bolge, S., Ruetsch, C. (2017). Assessment of rheumatoid arthritis quality process measures and associated costs. Population Health Management, 20 (1), 31-40.

Tkacz, J.P., Brady, B., Meyer, R., Lofland, J., Ruetsch, C., Prabhu, N. (2015). An assessment of the AGA and CCFA quality indicators in a sample of patients diagnosed with inflammatory bowel disease. Journal of Managed Care & Specialty Pharmacy, 21 (11), 1064-1076.

Brady, B.L., Tkacz, J.P., Lofland. J., Meyer, R., Bolge, S. (2015). Prescribing patterns of intravenous golimumab for rheumatoid arthritis. Clinical Therapeutics, 37 (9), 2028-2036.

Tkacz, J.P., Ingham, M.P., Brady, B., Meyer, R., Ruetsch, C. (2015). Novel adherence measures for infusible therapeutic agents indicated for rheumatoid arthritis. American Health and Drug Benefits, 8(9), 494-505.

Tkacz, J.P., Ellis, L., Meyer, R., Bolge, S., Brady, B.L., Ruetsch, C. (2015). Quality Process Measures for Rheumatoid Arthritis: Performance from Members Enrolled in a National Health Plan. Journal of Managed Care and Specialty Pharmacy.2015 Feb;21(2):135-43.

Tkacz, J.P., Volpicelli J., Un H., Ruetsch C. (2014). Relationship Between Buprenorphine Adherence and Health Service Utilization and Costs Among Opioid Dependent Patients. Journal Of Substance Abuse Treatment. 2014 Apr;46(4):456-62

Tkacz, J.P., Lofland, J.H., Vanderpoel, J., Ruetsch, C. (2014) Infliximab Dosing Patterns in a Sample of Patients with Crohn’s Disease: Results from a Medical Chart Review. American Health and Drug Benefits 2014 Apr;7(2):87-93.

Tkacz, J.P., Ellis, L., Bolge, S., Meyer, R., Brady, B.L., Ruetsch, C. (2014) Utilization and Adherence Patterns of Subcutaneously Administered Anti–Tumor Necrosis Factor Treatment Among Rheumatoid Arthritis Patients. Clinical Therapeutics 36(5). 2014 May;36(5):737-47

Ruetsch, C. (2014) Treating Prescription Opioid Dependence. The Journal of the American Medical Association 2014 Sep 17;312(11):1145-6

Tkacz, J.P., Ellis, L., Bolge, S., Meyer, R., Brady, B., & Ruetsch, C.  (2014).  Utilization and Adherence Patterns Associated with Subcutaneously Administered Anti-TNF Treatment Among Rheumatoid Arthritis Patients: An Analysis of Medical and Pharmacy Claims. Clinical Therapeutics, 2014 May;36(5):737-47

Tkacz, J.P., Lofland, J., Vanderpoel, J., Kardel, P., & Ruetsch, C.  (2014).  Infliximab dosing patterns among a sample of Crohn’s disease patients: Results from an integrated medical chart review. American Health and Drug Benefits, 2014 Apr;7(2):87-93.

Tkacz, J., Pesa, J., Vo, L., Kardel, P., Un, H., Volpicelli, J., Ruetsch, C. Opioid Analgesic–Treated Chronic Pain Patients at Risk for Problematic Use. American Journal of Managed Care, 19(11):871-880; 2013

Ruetsch, C., Tkacz, J., Kardel, P., Howe, A., Pai, H., & Levitan, B. Trajectories of health care service utilization and differences in patient characteristics among adults with specific chronic pain: analysis of health plan member claims. Journal Of Pain Research, 6, 137-149; 2013

Ruetsch, C., Tkacz, J., McPherson, T., & Cacciola, J. The effect of telephonic patient support on treatment for opioid dependence: Outcomes at one year follow-up. Addictive Behaviors, 37(5), 686-689; 2012

Tkacz, J., Severt, J., Kassed, C., & Ruetsch, C. Clinical Differences Between Opioid Abuse Classes Ameliorated After 1 Year of Buprenorphine-Medication Assisted Treatment. Journal Of Addictive Diseases, 31(2), 100-111; 2012

Tkacz, J. P., Severt, J., Ruetsch, C. Opioid relapse rates among a sample of new buprenorphine-medication assisted treatment patients: Relationship to compliance at one year follow-up.  American Journal on Addictions, 21(1), 55-62; 2012 

Ruetsch, C., Tkacz, J. P., Dewan, N.  Improving quality and accountability through information systems.  In Dewan, N., Luo, J., & Lorenzi, N. (Eds.), Information technology essentials for behavioral health clinicians.  New York: Springer; 2011   

Ruetsch, C., Cacciola, J., Tkacz, J.P.  A National Study of a Telephone Survey Support Service of Patients Receiving Office-Based Buprenorphine-Medication Assisted Treatment: Study Feasibility and Sample Description. Journal of Substance Abuse Treatment, 39(4), 307-317; 2010

Jan, S., Ruetsch, C., Nicholls, L., Bragaw, L.  Opioid Dependence: Managing the High Cost of Treatment Failure. Featured articles: Empirical View of Opioid Dependence; Opioid Dependence Treatment and Guidelines; Practice Strategies to Improve Compliance and Patient Self-Management. Supplement to Journal of Managed Care Physicians Vol. 16, No. 1-b; 2010

Albright, J., Ciaverelli, R., Essex, A., Tkacz, J.P., Ruetsch, C.  Psychiatrists Characteristics That Influence the Use of Buprenorphine-Medication Assisted Treatment. Journal of Addiction Medicine, 4(4), 197-203; December 2010

Ruetsch, C.  Opioid Dependence, the Criminal Justice System, and Buprenorphine-Medication Assisted Therapy. All Rise, Vol. 1, No. 1; 2009